No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Aura Biosciences, Inc. (AURA) stock was $6.16 as of Oct 6, 2026, 3:00 PM EDT, down 0.98% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +2.8% · 3-year avg -10.7%/yr
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments.
Biotechnology · Boston, MA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.37
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.48
vs Estimate
$-0.38
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AURA | $637.06M | $6.16 | -0.98% | +2.80% | N/A | N/A | N/A |
| 2OABI | $632.81M | $4.37 | -11.28% | +200.25% | -13.17% | N/A | vs AURA |
| 3PRME | $644.06M | $3.57 | +11.09% | -49.04% | N/A | N/A | vs AURA |
| 4ZVRA | $629.65M | $10.65 | -0.46% | +9.69% | +3.75% | -17.34% | vs AURA |
| 5SOPH | $625.02M | $7.45 | -9.15% | +85.81% | -13.62% | N/A | vs AURA |
| 6CLYM | $615.00M | $10.74 | -2.81% | +453.52% | N/A | N/A | vs AURA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 5 analysts
Average Price Target
$16.60
+169.5% upside
Low
$12.00
Current
$6.16
High
$23.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.44 | $-0.37 | $-0.30 | 3 |
| Quarter ending Dec 2026 | $-0.40 | $-0.35 | $-0.28 | 3 |
| Quarter ending Mar 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Quarter ending Jun 2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.77 | $-1.67 | $-1.55 | 3 |
| FY 2027 | $-1.78 | $-1.52 | $-1.26 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $8.99M | $19.20M | $29.41M | 4 |
| FY 2027 | $2.30M | $4.92M | $7.55M | 3 |
